GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cardio Diagnostics Holdings Inc (NAS:CDIO) » Definitions » Return-on-Tangible-Asset

CDIO (Cardio Diagnostics Holdings) Return-on-Tangible-Asset : -60.87% (As of Mar. 2025)


View and export this data going back to 2022. Start your Free Trial

What is Cardio Diagnostics Holdings Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Cardio Diagnostics Holdings's annualized Net Income for the quarter that ended in Mar. 2025 was $-6.54 Mil. Cardio Diagnostics Holdings's average total tangible assets for the quarter that ended in Mar. 2025 was $10.74 Mil. Therefore, Cardio Diagnostics Holdings's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2025 was -60.87%.

The historical rank and industry rank for Cardio Diagnostics Holdings's Return-on-Tangible-Asset or its related term are showing as below:

CDIO' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -245.93   Med: -139.26   Max: -90.24
Current: -90.24

During the past 5 years, Cardio Diagnostics Holdings's highest Return-on-Tangible-Asset was -90.24%. The lowest was -245.93%. And the median was -139.26%.

CDIO's Return-on-Tangible-Asset is ranked worse than
76% of 1500 companies
in the Biotechnology industry
Industry Median: -36.245 vs CDIO: -90.24

Cardio Diagnostics Holdings Return-on-Tangible-Asset Historical Data

The historical data trend for Cardio Diagnostics Holdings's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardio Diagnostics Holdings Return-on-Tangible-Asset Chart

Cardio Diagnostics Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Return-on-Tangible-Asset
-245.93 -118.10 -139.26 -170.70 -121.19

Cardio Diagnostics Holdings Quarterly Data
Dec20 Mar21 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -434.26 -144.46 -156.85 -88.51 -60.87

Competitive Comparison of Cardio Diagnostics Holdings's Return-on-Tangible-Asset

For the Biotechnology subindustry, Cardio Diagnostics Holdings's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cardio Diagnostics Holdings's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cardio Diagnostics Holdings's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Cardio Diagnostics Holdings's Return-on-Tangible-Asset falls into.


;
;

Cardio Diagnostics Holdings Return-on-Tangible-Asset Calculation

Cardio Diagnostics Holdings's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=-8.383/( (3.925+9.909)/ 2 )
=-8.383/6.917
=-121.19 %

Cardio Diagnostics Holdings's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2025 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=-6.54/( (9.909+11.579)/ 2 )
=-6.54/10.744
=-60.87 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2025) net income data.


Cardio Diagnostics Holdings  (NAS:CDIO) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Cardio Diagnostics Holdings Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Cardio Diagnostics Holdings's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Cardio Diagnostics Holdings Business Description

Traded in Other Exchanges
N/A
Address
311 West Superior Street, Suite 444, Chicago, IL, USA, 60654
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.
Executives
Robert Philibert director, 10 percent owner, officer: Chief Medical Officer 400 N. ABERDEEN, SUITE 900, CHICAGO IL 60642
Timur Dogan officer: Chief Technology Officer 400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Meeshanthini Dogan director, 10 percent owner, officer: Chief Executive Officer 400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Warren Hosseinion director C/O 1668 S. GARFIELD AVENUE, 2ND FLOOR, ALHAMBRA CA 91801
Elisa V Luqman officer: Chief Financial Officer 37 HARRISON DRIVE, NORTHPORT NY 11768
Khullani Abdullahi officer: VP of Revenue and Strategy 400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Brandon Sim director C/O APOLLO MEDICAL HOLDINGS, INC., 1668 S. GARFIELD AVENUE, 3RD FLOOR, ALHAMBRA CA 91801
James Intrater director C/O CARDIO DIAGNOSTICS HOLDINGS INC., 400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Oded Levy director C/O CARDIO DIAGNOSTICS HOLDINGS INC., 400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Stanley K. Lau director C/O CARDIO DIAGNOSTICS HOLDINGS INC., 400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Bd Holding, Inc. 10 percent owner 15 PROSPECT PLACE, IOWA CITY IA 52246
Jonathan Intrater officer: CEO 223 PALMER STREET, PALMER MA 01069
Allan Liu director 1600 PARKWOOD CIRCLE, STE 200, ATLANTA GA 30339-2119
Loren Mortman director 207 EAST 74TH STREET, APARTMENT 10F, NEW YORK NY 10021
Mana Capital Llc 10 percent owner 8 THE GREEN, SUITE A, DOVER DE 19901

Cardio Diagnostics Holdings Headlines

From GuruFocus